Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tivantinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 36 for your search:
Start Over
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-A-U302, 2010-022365-10, NCT01244191
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ197-006, NCT01377376
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ197-A-U252, NCT01075048
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
Phase: Phase II, Phase I
Type: Treatment
Status: Enrolling by invitation
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-299, NCT01178411
Phase 2 Study in Patients With MiT Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-204, NCT00557609
A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-205, NCT00558207
A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-209, NCT00777309
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-215, NCT00988741
ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-A-U251, NCT01055067
Study of ARQ 197 Monotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-004, NCT01152645
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-218, NCT01395758
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03470, CDR0000712984, 2011-0197, 8984, U01CA062461, P30CA016672, N01CM00039, MDA-2011-0197, NCT01447914
Tivantinib in Treating Patients With Metastatic Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00237, CDR0000721410, OSU11132, 8986, N01CM00070, N01CM00071, N01CM00100, N01CM62207, P30CA016058, U01CA062491, NCT01519414
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00722, DFCI-12-017, CDR0000730102, 12-017, 8985, P30CA006516, U01CA062490, NCT01575522
ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-007, 23-4882, NCT01580735
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-01641, SWOG-S1107, S1107, U10CA180888, U10CA032102, NCT01688973
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01640, 478834, 12-1359, 9165, N01CM00038, N01CM00071, N01CM00099, P30CA014599, NCT01696955
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00937, 12-2158, 9267, N01CM00071, P30CA014599, NCT01861301
ARQ 197 in Subjects With Metastatic Solid Tumors
Phase: Phase I
Type: Tissue collection/Repository
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-101, NCT00302172
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-0701, NCT00609921
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-103, NCT00612209
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-111, NCT00612703
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-114, NCT00802555
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-116, NCT00827177
Start Over